No Data
No Data
Mural Oncology Initiated at Buy by Rodman & Renshaw
Rodman & Renshaw Initiates Coverage On Mural Oncology With Buy Rating, Announces Price Target of $15
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Mural Oncology Presents Clinical Data From ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology | 10-Q: Quarterly report
No Data